Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing in ovarian cancer cell line HEYA8 in terms of ECM1 silencing and reintroduction of ECM1 subtypes ECM1a and ECM1b

ABSTRACT: RNA sequencing in ovarian cancer cell line HEYA8 in terms of ECM1 silencing and reintroduction of ECM1 subtypes ECM1a and ECM1b

PROVIDER: PRJNA719542 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14139654_1.fastq.gz	Fastqsanger.gz
	SRR14139654_2.fastq.gz	Fastqsanger.gz
	SRR14139655_1.fastq.gz	Fastqsanger.gz
	SRR14139655_2.fastq.gz	Fastqsanger.gz
	SRR14139656_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

RNA sequencing in ovarian cancer cell line HEYA8 in terms of ECM1 silencing and reintroduction of ECM1 subtypes ECM1a and ECM1b

Project description:Extracellular Matrix Protein-1 (ECM1) promotes tumorigenesis in multiple organs, but the mechanisms associated with the functions and putative receptors of ECM1 subtypes have yet to be systematically clarified. We found in this study that secretory ECM1a functions as an oncoprotein to induce tumorigenesis through binding of the Gly-Pro-Arg (GPR) motif to integrin aXb2 and activation of AKT/FAK/Rho/cytoskeletal signaling. Nonsecretory ECM1b binds to myosin to block myosin phosphorylation, thus preventing cytoskeletal signaling activation and tumorigenesis. Based on RNA sequencing, we further found that the heterogeneous nuclear ribonucleoprotein L-like (hnRNPLL) protein induced by ECM1a favors the alternative mRNA splicing of ECM1a to control ECM1-associated signaling and tumorigenesis. ATP binding cassette subfamily G member 1 (ABCG1) transduces ECM1a-integrin aXb2 interactive signaling to facilitate the phosphorylation of AKT/FAK/Rho/cytoskeletal molecules and to confer cisplatin resistance in cancer cells through upregulation of CD326-mediated cell stemness.

2021-05-27 | GSE171425 | GEO

Transcription profiling of mouse Scl -/- yolk sac cell line after reintroduction of Scl by protein transduction

Project description:Expression profile of Scl -/- yolk sac cell line after reintroduction of Scl

2008-01-09 | E-TABM-397 | biostudies-arrayexpress

Reframing gene essentiality in terms of adaptive flexibility

Project description:Reframing gene essentiality in terms of adaptive flexibility

| PRJNA481727 | ENA

Human, ovarian epithelial cancer cell line, LC-MSMS

Project description:We investigated the functions of ECM1 subtypes ECM1a (inlcuding wild type and mutant) and ECM1b in ovarian cancer cell line HEYA8. While ECM1a is oncogenic, ECM1b is a tumor suppressor. To identify the molecules binding to ECM1a or ECM1b within cells, protein samples were generated by co-IP using HA antibody to pull down proteins potentially binding to ECM1a (HA-tagged) (samples: P20170700270A1/A2/A3/A4) or ECM1b (HA-tagged) (samples: P20170700270B1/B2/B3/B4) within cells indicated in gel image P20170700270. To identify more cell surface markers besides integrins alpha X and beta 2 binding to ECM1a-WT or ECM1a-MT, three batches of protein samples were generated by co-IP using HA antibody to pull down total proteins binding to ECM1a-WT or ECM1a-MT shown in gel image R20191201880, or to pull down membrane fractionation proteins binding to ECM1a-WT or ECM1a-MT indicated in gel image 20200100053, or to pull down membrane fractionation proteins of HEYA8 cells treated with ECM1a-WT or ECM1a-MT conditioned media binding to ECM1-WT or ECM1a-MT shown in gel image 20200100054.

2021-05-27 | PXD025239 | Pride

RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)

Project description:Some data have suggested a clinical survival benefit related to the reintroduction of anti-EGFRs therapy in patients with metastatic colorectal cancer (mCRC). Based on resistance mechanisms related to the development of resistant clones, the investigators could assume that patients who benefited most from the reintroduction of anti-EGFRs were those who, through interval chemotherapy, had no longer mutated RAS clone in plasma that appeared during the progression with the first anti-EGFR treatment. Conversely, those who did not benefit from this therapy were probably patients who had mutated RAS clones circulating at the time of reintroduction of anti-EGFRs. To support this hypothesis, investigators propose to evaluate the correlation between the eventual presence of RAS mutations in circulating blood and the efficacy of an anti-EGFR therapy reintroduction in patients with mCRC.

| 2252506 | ecrin-mdr-crc

New Stx subtypes

Project description:New Stx subtypes

| PRJEB38687 | ENA

Dual Morphologic Subtypes of High-Grade Serous Ovarian Cancer

Project description:We identified novel, gross morphology-based subtypes of high-grade serous ovarian cancer, with unique clinical features and molecular signatures.

2022-05-31 | GSE204748 | GEO

Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer

Project description:The purpose of this study is to evaluate the feasibility and efficacy of first-line FOLFIRI discontinuation after initial 8 cycles and reintroduction after progression.

| 2028513 | ecrin-mdr-crc

DUSP4 silencing

Project description:DUSP4 silencing

| PRJNA897936 | ENA

Dual Morphologic Subtypes of High-Grade Serous Ovarian Cancer

Project description:Dual Morphologic Subtypes of High-Grade Serous Ovarian Cancer

| PRJNA842074 | ENA